Skip to content
Search

Latest Stories

Submit Guest Post

New York, London keep top spots in global financial centres index

New York, London keep top spots in global financial centres index

NEW YORK easily kept the top spot in the latest Global Financial Centres Index (GFCI), while London held on to second place as Chinese cities slipped, according to the ranking published on Friday (24).

The index, published by the Z/Yen Group in partnership with think-tank China Development Institute, will come as a relief to London in particular after it lost access to the European Union financial market when Britain completed its journey out of the bloc's orbit last December.


"The relatively strong performance of New York and London suggests that the financial services sectors in these cities managed to sustain their performance despite radical changes in working practices during the last 18 months," GFCI said in a statement.

Hong Kong and Singapore in third and fourth position both fell 25 points in the ratings.

"We see two patterns in the results for GFCI 30 – confidence in the recovery of the North American and Western European economies following the shock of 2020; and a levelling off following the rapid rise of Asia/Pacific centres and their economic stability in the Covid-19 pandemic," said Michael Mainelli, executive chairman of Z/Yen.

"Competition remains tight. Outside the top two centres, only five points on a 1,000 point scale separate the centres ranked third to eighth."

In their survey of fintech centres, New York and Shanghai retained first and second positions, with London rising two places to third place as Britain makes fintech-friendly policies a priority.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less